Observations have been made of pupil size, as affected by intravenously administered atropine and neostigmine, and by extubation, during reversal of curarization. Pulse rate and blood pressure changes were also recorded. Some degree of mydriasis was observed in 70 per cent of patients after atropine, in 86 per cent after neostigmine, and in 55 per cent at extubation. Pulse rate increased in 88 per cent after atropine and decreased in 86 per cent after neostigmine. Blood pressure rose in 70 per cent after atropine and in 58 per cent after neostigmine. Extubation caused no consistent pulse and blood pressure changes. It was considered that the pupillary changes noted would not be deleterious in intra-ocular surgery.
For several years, approximately 25 per cent of phate injected intravenously at the end of an all intra-ocular operations in this hospital have been performed with a full relaxant-type general anaesthetic with endotracheal intubation. As d-tubocurarine has been the principal muscle relaxant used, atropine and neostigmine have been injected at the end of operation to reverse residual curarization. Atropine and allied belladonna drugs have long been known for their mydriatic effects but Goodman and Gilman (1955a) state that neostigmine does not have much effect on the pupil. Are these drugs, when injected intravenously at the end of an operation, harmful to the intra-ocular surgery performed?
Studies on intramuscularly administered atropine by Leopold and Comroe (1948) , Schwartz, de Roetth and Papper (1957) and Herxheimer (1958) suggest that it does not produce a strong pupillary dilatation. Schwartz, de Roetth and Papper (1957) also show the safety of atropine and hyoscine when given pre-operatively to glaucomatous patients. However, there is little information about the effects of atropine and neostigmine on pupil size, when given intravenously at the end of operation, or if these drugs so used are contraindicated in intra-ocular surgery.
STUDY
A study was made to determine the pupillary effects of atropine sulphate and neostigmine methyl sul-795 operation. Note was also made of the effects of extubation on pupil size. Concurrently with the above observations, records were made of the effects of the atropine, neostigmine and extubation on the pulse rate and systolic blood pressure.
It is stressed that we wished to find what changes occurred in normal clinical circumstances, so fifty adult patients having general anaesthetics for routine surgical conditions were studied. Premedication was not standardized, being morphine, pethidine or papaveretum with atropine or hyoscine. Anaesthesia was induced with thiopentone, intubation was facilitated by injection of suxamethonium chloride, and anaesthesia was maintained with nitrous oxide, oxygen and d-tubocurarine or gallamine. Hyperventilation of the lungs was effected by manual intermittent positive pressure respiration. At the end of the operation atropine was given intravenously and observations were made of pupil size, pulse rate and systolic blood pressure, every 2 minutes for 10 minutes, at which time neostigmine was given intravenously and further observations were made at 2-minute intervals. The effects of extubation on the pulse, systolic blood pressure and pupil size were noted in most cases. During this period artificial pulmonary ventilation was continued until spontaneous respiration was clinically adequate. Pulse rate was measured by counting the signals from a pulse monitor and blood pressure was determined manually from the radial pulse with the cuff of a standard mercury sphygmomanometer round the upper arm. Pupillary size was estimated by inspection, and an arbitrary scale of 1 to 10 was adopted for pupil diameter, 1 being pinpoint, 5 half-dilated and 10 fully dilated. Both workers cross-checked each other's estimations from time to time to standardize measurements. Late in the series, pupil diameters were measured directly and correlated with our scale. It was found that a size 1 pupil was approximately 1.5 mm in diameter, a size 10 was 6 mm, and a difference of 1 unit was approximately 0.5 mm. The method of assessing pupil diameter provided a rapid estimation of change in pupil size not possible with direct measurement, and while not entirely accurate, both workers found it gave good correlation in their cross-checks.
The doses of atropine and neostigmine given to each patient were determined by age, weight, general condition and effect of relaxant drugs.
RESULTS
The results are presented in two parts:
Pupillary changes after injection of atropine and neostigmine and associated with extubation. Pulse and systolic blood pressure changes after injection of atropine and neostigmine, and associated with extubation. It was realized that the premedicant drugs might affect the overall results. As a number of combinations of drugs were used, and some groups were small, this did not allow any accurate comparison. The overall impression was that different premedicants did not affect the results.
Pupillary Changes.
An initial intravenous dose of atropine 0.9 mg or 1.2 mg was given, and the results were analyzed according to which of these doses was used. Twentyseven patients were given atropine 0.9 mg and twenty-three atropine 1.2 mg. Pupillary changes have been recorded in table I under the following headings: (i) maximum change at any time between 0 and 10 minutes; (ii) difference in pupil size at 0 and 10 minutes. Table I shows the maximum changes following both doses within the 10-minute period. Of the fifty patients 62 per cent (31) showed increases of less than 3 units (1 mm), 30 per cent (15) showed either no change or a decrease in pupillary size and 8 per cent (4) an increase of more than 1 mm. At the end of 10 minutes, 42 per cent (21) of all cases showed increases of less than 3 units (1 mm), 56 per cent (28) showed either no change or a decrease in size, and 2 per cent (1) an increase of more than 1 mm. Thus there was a tendency after 10 minutes for the pupil diameter to decrease slightly from its maximum dilatation. Individual case records show that if the pupil was large at the beginning of the study, increases in size could make it widely dilated, although the maximum change in size was only average (e.g. less than 3 units). In one patient atropine 0.9 mg caused a pupil increase of 2 units to a maximum of 6 units, while with atropine 1.2 mg in two patients dilatation to a maximum of 8 units, one from 5 units and the other from 6 units, was observed. After neostigmine, the results have been analyzed in five groups, depending on the combinations of atropine and neostigmine used:
Atropine 0.9 mg with neostigmine 1.25 mg (20). Atropine 0.9 mg with neostigmine 2.5 mg (2). Atropine 1.2 mg with neostigmine 1.25 mg (5) Atropine 1.2 mg with neostigmine 2.5 mg (17). Atropine 0.9 + 0.3 mg with neostigmine 2.5 mg (6)-patients to whom further atropine was given with the neostigmine. Table II shows the difference in pupillary size when the final reading was at 20 minutes and the initial reading was at 10 minutes, i.e. when the neostigmine was given. This table shows that in 36 per cent of all cases (18) there were increases of less than 3 units dilatation difference at the times stated, with 60 per cent (30) showing no change or miosis, and 4 per cent (2) an increase in diameter greater than 1 mm. Table III shows the differences between the final reading at 20 minutes and the initial reading at 0 minutes (the original pupil size before atropine injection). In the table, 42 per cent (21) of patients showed less than 3 units dilatation increase from the original pupil size, 44 per cent (22) showed no change or a diminution in size, and 14 per cent (7) an increase of more than 1 mm. Table IV shows the maximum pupillary changes occurring at any moment during the 10-minute period after the neostigmine was injected. From table IV it can be seen that 70 per cent of cases (35) showed maximum changes of less than 3 units, 14 per cent (7) showed no change or a miosis, and 16 per cent (8) had increases over 1 mm.
Comparison of the results shown in tables II and IV shows that there is a tendency for the pupil to decrease from its maximum dilatation by the end of this 10-minute period. The maximum pupil sizes after neostigmine (also associated with extubation and wakening-vide infra) were 8 units (one patient), 7 units (one patient) and 6 units (two patients). In eight patients the pupil dilated to 5 units and in the remaining thirty-nine patients dilatation reached a maximum diameter of less than 5 units. Table V shows pupillary changes after extubation in forty-five patients. In 48.4 per cent of patients (22) the pupils increased in size less than 3 units. In 44 per cent (20) no change or a constriction was observed and in 6.6 per cent (3) increases of more than 1 mm diameter were noted. Table VI summarizes the changes which occurred after injection of atropine and neostigmine and in association with extubation. Some degree of mydriasis occurred in 70 per cent of all patients (35) after atropine, in 86 per cent (43) after neostigmine and in 55 per cent (25) at the time of extubation. In a proportion of patients no change was observed, whilst in 4.4 per cent (2) to 14 per cent (7) some degree of pupillary constriction was evident.
It is interesting that in 56 per cent (28) of all patients the pupils showed no change, or even some constriction, during the 10 minutes following the atropine injection, when some degree of dilatation would have been expected. The lightening of the level of anaesthesia may have been a factor here, because a number of patients began to breathe spontaneously during this period. During the period following the injection of neostigmine the anaesthetic level was decreased, so that while pupillary changes were attributed to the neostigmine, some of the results are partly due to the lightening level of anaesthesia with reactions to painful stimuli and the effects of extubation. It was not possible to differentiate between these three factors. What has been recorded is the effect of anaesthetic management on the pupil during this period. The 59.4 per cent (27) of patients showing changes with extubation will also be noted in table IV. This study shows that injection of atropine and neostigmine, and extubation (including painful stimuli) cause pupillary changes. In the majority of cases dilatation or constriction is slight, the change in diameter being 1 mm or less. Do these changes produce any harmful effects on the eye in which intra-ocular surgery has been performed? It is usual to instill either atropine or physostigmine (eserine) after surgery to produce either mydriasis or miosis. These topically applied solutions contain a much higher total quantity of the drugs than could reach the eye as a unit of intravenous injection, so producing a more powerful effect. It is unlikely that the drugs given intravenously will affect the mydriasis or miosis produced by the local instillations. Whilst atropine is an antagonist to physostigmine (Goodman and Gilman, 1955b) , it is unlikely that the intravenous atropine will dilate the pupil already constricted by physostigmine. However, it must be remembered that all components studied can have an action on the pupil, either dilatating or constricting it. While we feel that these effects will not nullify pupillary changes produced by local instillations to an eye, efforts should be made to keep their effects to a minimum, especially reflexes due to painful stimuli and extubation.
Changes in Pulse Rate and Blood Pressure.
In fifty patients pulse and systolic blood pressure recordings were made at 2-minute intervals for 10 minutes after the administration of atropine. The neostigmine was injected and recordings were made for a further 10 minutes. The results are shown in table VII.
Effects of atropine.
In 88 per cent of the patients (44) there was a rise in pulse rate after atropine, varying from 4 to 72 beats/min. The majority of these (93 per cent, 41 cases) increased by 10 to 50 beats per minute ( fig. 1 ). Maximum pulse rates were 144, 156 and 168 beats/min, one rate being doubled after atropine. There appeared to be no appreciable difference in pulse changes whether 0.9 or 1.2 mg of atropine had been given. fig. 2) . Again, the different doses of atropine appeared to have no effect. The correlation of pulse and blood pressure was interesting. Of the forty-four who showed cardiac acceleration, blood pressure rose in 68 per cent (30), remained steady in 14 per cent (6), but fell in 18 per cent (8). Of the four cases with cardiac slowing, one had a fall in blood pressure while three showed a rise. The pressure rose after atropine in the two patients in whom the pulse remained the same.
Effects of neostigmine.
Pulse rate was affected considerably, 86 per cent (43) developing bradycardia after neostigmine administration. The degree of cardiac slowing was quite marked, in spite of the prior administration of atropine, ranging from a decrease of 4 to 60 beats/min. The majority (84 per cent; 36 cases) slowed 10 to 36 beats/min ( fig. 3 ) and the lowest actual rates recorded were 48,60 and 60 beats/min. In these few cases further atropine was given because of the unduly slow rhythm. There was no obvious difference in pulse or blood pressure changes, whether neostigmine 1.25 or 2.5 mg had been given.
Fifty-eight per cent of patients (29) showed an elevation of blood pressure, and 20 per cent (10) (26) had a pressure rise, 21 per cent (9) had a fall and in 18.5 per cent (8) the pressure remained steady. Of the four cases with tachycardia, two had a rise in pressure, one had a fall and one remained steady. Of the three cases with no change in pulse rate, two maintained a steady blood pressure while one showed an elevation. 
Effects of extubation.
Extubation had a varying effect on pulse rate (41 cases), 39 per cent (16) showing an increase, 27 per cent (11) a decrease and 34 per cent (14) no change. The pulse rise varied from 4 to 48 beats/min, the majority being in the 10-30 range. Pulse falls varied from 4 to 40 beats/min, being fairly evenly spread in this range ( fig. 5 ). Blood pressure (forty-two cases) increased in seventeen patients (40 per cent), decreased in ten (24 per cent) and showed no change in fifteen (36 per cent). These changes were mainly of the order of 10 to 20 mm Hg (fig. 6) .
A pulse monitor (Burdick Telecor) was used in most patients throughout the study, and no cardiac arrhythmias were noted. While this is not ideal, it was felt that this gave a better chance of detection of arrhythmias than did mere palpation of the pulse. Unfortunately, it was not possible to obtain electrocardiographic tracings on these patients. Bain and Broadbent (1949) have stated that atropine may cause an initial slowing of the pulse rate, but Hunter (1953) and Wood-Smith and Stewart (1962a) state that this does not occur after intravenous injection. In only one of our forty-four patients who had pulse acceleration was there an initial slowing. On the other hand, four patients did show cardiac slowing without a subsequent acceleration, two of these cases returning to the pre-atropine pulse rate after several minutes. Of these five cases with pulse slowing, and in the two cases with no change, the rate had been-rapid (approximately 120 beats/min) in five before atropine was injected. Morton and Thomas (1958) have shown that initial slowing does not occur after intravenous atropine if the dose is large and is given rapidly (e.g. more than 0.6 mg in less than 2.5 minutes), or if atropine or hyoscine has been given previously as part of premedication. All patients in this series who showed pulse slowing had had long operations, so that the pre-operative atropine had been given 3 to 4 hours prior to the intravenous atropine. This may have contributed to the slowing even though the intravenous atropine was given rapidly.
DISCUSSION
A rise of blood pressure in the majority of cases after atropine supports findings quoted by Eger (1962) .
Bradycardia after neostigmine was expected (Wylie and Churchill-Davidson, 1960a) , but the degree of cardiac slowing was quite marked, so that several cases required further atropine. WoodSmith and Stewart (1962b) state that blood pressure falls after the injection of neostigmine, but in this series more showed an elevation than a depression. They further state, however, that when neostigmine and atropine have both been administered, the net result may be a rise in blood pressure and pulse rate. This concurs with our figures for blood pressure, but certainly not with our findings for heart rate. However, it must be remembered that the patients were beginning to awaken and to breathe spontaneously during this period, so that changes in blood pressure and pulse were not necessarily due to neostigmine alone, but could be associated with physical stimuli.
Extubation showed no consistent effect on pulse and blood pressure, though there was a sufficient number showing pulse slowing (27 per cent; 11 cases) to cause concern, particularly if this should be associated with a marked slowing produced by neostigmine. Converse, Landmesser and Harmel (1952) state that there is a considerable incidence of arrhythmias on extubation in light planes of anaesthesia, and Shumacker and Hampton (1951) report five cases of cardiac arrest following extubation. In four of these, death was associated directly with tracheobronchial suction and. extubation, and they sugget>t that hypoxia and vagal reflexes are involved in the cause of these mishaps. Riding and Robinson (1961) show that cardiac irregularities are likely to occur with neostigmine if respiratory acidosis develops, so that a combination of neostigmine, extubation, hypoxia and lespiratory acidosis may well produce arrhythmias or even arrest.
However, vagal stimulation may not be the only reaction to extubation, for 39 per cent of our patients showed a tachycardia, 40 per cent a blood pressure rise and 55 per cent pupillary dilatation after extubation, so there seems a good case for postulating the presence of an orthosympathetic response. This response is described by Johnstone and Nisbet (1961) and Stephen and Little (1961) as a result of intubation, and there seems no reason why it should not occur following extubation.
In conclusion, then, the major effect of intravenous atropine is to produce tachycardia, but if neostigmine is given 10 minutes after atropine, a marked bradycardia may supervene and this, coupled with bradycardia due to extubation, is undesirable. Thus it appears that a 10-minute interval between atropine and neostigmine is too long. Wylie and Churchill-Davidson (1960b) state that 2 to 5 minutes is the optimum, and Kemp and Morton (1962) show that both drugs may be given simultaneously with safety. As stated before, the atropine in these cases was given rapidly, but the neostigmine was given slowly over 2 minutes. Less marked changes with neostigmine may have resulted if this drug had been given even more slowly.
If spontaneous respiration became clinically adequate during the period under study, no attempt was made to maintain anaesthesia or controlled respiration, as did Kemp and Morton (1962) , because it was desired to observe what actually happened to pupil size, pulse rate and blood pressure at the completion of a "normal" anaesthetic.
Blood pressure changes should not cause concern unless the patient is hypertensive prior to administration of atropine and neostigmine and an elevation follows, or when he is hypotensive prior to atropine and neostigmine and the pressure falls. 
